gynécologie et obstétrique
Sécurité des médicaments pendant la grossesse
Références
1.Centers for Disease Control and Prevention (CDC): Update on overall prevalence of major birth defects--Atlanta, Georgia, 1978-2005.MMWR Morb Mortal Wkly Rep57(1):1-5, 2008. 2.Feldkamp ML, Carey JC, Byrne JLB, Krikov S, Botto LD: Etiology and clinical presentation of birth defects: population based study.BMJ357:j2249, 2017. Publié le 30 mai 2017. doi:10.1136/bmj.j2249 3.U.S. Food and Drug Administration (FDA): FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. FDA News Release, August 21, 2023. 4.Garneau WM, Jones-Beatty K, Ufua MO, et al: Analysis of clinical outcomes of pregnant patients treated withnirmatrelvirandritonavirfor acute SARS-CoV-2 infection.JAMA Netw Open5(11):e2244141, 2022. Publié le 1 novembre 2022. doi:10.1001/jamanetworkopen.2022.44141 5.Liggins GC, Howie RN: A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants.Pediatrics50(4):515-525, 1972. 6.Bennett HA, Einarson A, Taddio A, et al: Prevalence of depression during pregnancy: systematic review [published correction appears inObstet Gynecol103(6):1344, 2004].Obstet Gynecol103(4):698-709, 2004. doi:10.1097/01.AOG.0000116689.75396.5f 